Brickell Biotech to Report Second Quarter 2020 Financial Results and Provide a Corporate Update on August 12, 2020
03 Août 2020 - 10:05PM
Brickell Biotech, Inc. (“Brickell”) (Nasdaq: BBI), a clinical-stage
pharmaceutical company focused on developing innovative and
differentiated prescription therapeutics for the treatment of
debilitating skin diseases, today announced that it will report its
financial results for the second quarter ended June 30, 2020, after
the market close on Wednesday, August 12, 2020. Brickell’s
management will host a conference call and webcast at 4:30pm ET to
discuss the financial results and recent corporate highlights.
To access the call, please dial 877-705-6003 in the
U.S. or 201-493-6725 outside the U.S. and provide the conference ID
number: 13706625. To access the live webcast, please go to the
investors section of Brickell’s website at
https://ir.brickellbio.com/events-presentations. Following the live
webcast, an archived version of the call will be available on the
website.
About Brickell BioBrickell
Biotech, Inc. is a clinical-stage pharmaceutical company focused on
developing innovative and differentiated prescription therapeutics
for the treatment of debilitating skin diseases. Brickell’s
pipeline consists of potential novel therapeutics for hyperhidrosis
and other prevalent dermatological conditions. Brickell’s executive
management team and board of directors bring extensive experience
in product development and global commercialization, having served
in leadership roles at large global pharmaceutical companies and
biotechs that have developed and/or launched successful products,
including several that were first-in-class and/or achieved iconic
status, such as Cialis®, Taltz®, Gemzar®, Prozac®,
Cymbalta® and Juvederm®. Brickell’s strategy is to leverage
this experience to in-license, acquire, develop, and commercialize
innovative products that Brickell believes can be successful in the
currently underserved dermatology global marketplace. For more
information, visit http://www.brickellbio.com.
Brickell Investor
Contact:IR@brickellbio.com
Brickell Biotech (NASDAQ:BBI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Brickell Biotech (NASDAQ:BBI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
Real-Time news about Brickell Biotech Inc (NASDAQ): 0 recent articles
Plus d'articles sur